Company
Headquarters: West Conshohocken, PA, United States
Employees: 71
CEO: Dr. Paul A. Friedman M.D.
$13.49 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-à agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $740.6 M |
| EBITDA | $-306,007,008 |
| Gross Profit TTM | $705.5 M |
| Profit Margin | -39.04% |
| Operating Margin | -39.68% |
| Quarterly Revenue Growth | 362.00% |
Madrigal Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: MDGL wb_incandescent
Stock: FSX: YDO1 wb_incandescent